Intercept Pharmaceuticals Stock Cash And Equivalents
| ICPTDelisted Stock | USD 10.31 0.16 1.53% |
Intercept Pharmaceuticals fundamentals help investors to digest information that contributes to Intercept Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Intercept Stock. The fundamental analysis module provides a way to measure Intercept Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intercept Pharmaceuticals stock.
Intercept |
Intercept Pharmaceuticals Company Cash And Equivalents Analysis
Intercept Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Intercept Pharmaceuticals Cash And Equivalents | 404.78 M |
Most of Intercept Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intercept Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Intercept Pharmaceuticals has 404.78 M in Cash And Equivalents. This is 50.69% lower than that of the Biotechnology sector and 9.47% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 85.02% higher than that of the company.
Intercept Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intercept Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intercept Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Intercept Pharmaceuticals by comparing valuation metrics of similar companies.Intercept Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Intercept Fundamentals
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 | |||
| Profit Margin | (0.19) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 695.84 M | |||
| Shares Outstanding | 41.81 M | |||
| Shares Owned By Insiders | 3.12 % | |||
| Shares Owned By Institutions | 81.30 % | |||
| Number Of Shares Shorted | 10.19 M | |||
| Price To Earning | (3.88) X | |||
| Price To Book | 44.19 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 285.71 M | |||
| Gross Profit | 284.73 M | |||
| EBITDA | (61.7 M) | |||
| Net Income | (174.86 M) | |||
| Cash And Equivalents | 404.78 M | |||
| Cash Per Share | 13.58 X | |||
| Total Debt | 332.67 M | |||
| Debt To Equity | 411.20 % | |||
| Current Ratio | 3.22 X | |||
| Book Value Per Share | 1.72 X | |||
| Cash Flow From Operations | (26.78 M) | |||
| Short Ratio | 2.64 X | |||
| Earnings Per Share | (4.26) X | |||
| Price To Earnings To Growth | (0.69) X | |||
| Target Price | 19.0 | |||
| Number Of Employees | 341 | |||
| Beta | 0.88 | |||
| Market Capitalization | 794.36 M | |||
| Total Asset | 553.71 M | |||
| Retained Earnings | (2.14 B) | |||
| Working Capital | 310.05 M | |||
| Current Asset | 641.69 M | |||
| Current Liabilities | 47.37 M | |||
| Z Score | -3.15 | |||
| Net Asset | 553.71 M |
About Intercept Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intercept Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intercept Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intercept Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |